Prelude Capital Management’s Gain Therapeutics GANX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $64.5K | Hold |
35,820
| – | – | 0.01% | 943 |
|
|
2025
Q1 | $68.4K | Hold |
35,820
| – | – | 0.01% | 986 |
|
|
2024
Q4 | $77.4K | Hold |
35,820
| – | – | ﹤0.01% | 989 |
|
|
2024
Q3 | $63.8K | Hold |
35,820
| – | – | ﹤0.01% | 1092 |
|
|
2024
Q2 | $45.9K | Hold |
35,820
| – | – | ﹤0.01% | 1056 |
|
|
2024
Q1 | $135K | Sell |
35,820
-22,280
| -38% | -$84K | 0.01% | 1059 |
|
|
2023
Q4 | $190K | Hold |
58,100
| – | – | 0.01% | 826 |
|
|
2023
Q3 | $191K | Hold |
58,100
| – | – | 0.01% | 775 |
|
|
2023
Q2 | $260K | Hold |
58,100
| – | – | 0.02% | 616 |
|
|
2023
Q1 | $280K | Hold |
58,100
| – | – | 0.02% | 599 |
|
|
2022
Q4 | $182K | Hold |
58,100
| – | – | 0.01% | 857 |
|
|
2022
Q3 | $189K | Hold |
58,100
| – | – | 0.01% | 1058 |
|
|
2022
Q2 | $209K | Hold |
58,100
| – | – | 0.01% | 1073 |
|
|
2022
Q1 | $238K | Hold |
58,100
| – | – | 0.01% | 925 |
|
|
2021
Q4 | $315K | Hold |
58,100
| – | – | 0.01% | 1008 |
|
|
2021
Q3 | $433K | Hold |
58,100
| – | – | 0.01% | 721 |
|
|
2021
Q2 | $581K | Hold |
58,100
| – | – | 0.02% | 678 |
|
|
2021
Q1 | $867K | Buy |
+58,100
| New | +$867K | 0.02% | 406 |
|